Drug Trial Radar · NCT00855465
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Last checked: Nov 20, 2026Latest source record: Nov 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
262
Actual
Start
Feb 23, 2009
Primary completion
Jun 27, 2012
Study completion Jun 27, 2012
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Mar 4, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Conditions
- Pulmonary Hypertension
Interventions
Riociguat (Adempas, BAY63-2521)Drug
BAY63-2521: 1 mg tid - 2,5 mg tid orally for 16 weeks.
PlaceboDrug
Matching Placebo tid orally for 16 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 16Time frame: Baseline and week 16
Locations
89 sites in 26 countries. Site status is shown where the registry gives one.
Site not named
La Jolla, California
Site not named
Sacramento, California
Site not named
Miami, Florida
Site not named
Iowa City, Iowa
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Cleveland, Ohio
Site not named
Columbus, Ohio
Site not named
Dallas, Texas
Site not named
Corrientes, Argentina
Site not named
Prahran, Victoria, Australia
Site not named
Innsbruck, Austria
Site not named
Vienna, Austria
Site not named
Bruxelles - Brussel, Belgium
Site not named
Leuven, Belgium
Site not named
Rio de Janeiro, Brazil
Site not named
Porto Alegre, Rio Grande do Sul, Brazil
Site not named
São Paulo, São Paulo, Brazil
Site not named
Calgary, Alberta, Canada
Site not named
London, Ontario, Canada
Site not named
Ottawa, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Shanghai, China
Site not named
Qingdao, Shandong, China
Vseobecna fakultni nemocnice
Prague, Czechia
Site not named
Aarhus N, Denmark
Site not named
Brest, France
Site not named
Caen, France
Hopital Antoine Beclere
Clamart, France
Site not named
Lille, France
Site not named
Nice, France
Site not named
Pessac, France
Site not named
Rouen, France
Site not named
Vandœuvre-lès-Nancy, France
Site not named
Hamburg, Germany
Site not named
Heidelberg, Baden-Wurttemberg, Germany
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.